Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Pick Your #1 Japanese Food - 2Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- 3Portable Installment Answers for Independent ventures
- 4Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- 5Thousands of ultra-orthodox protest in Jerusalem against conscription
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- Your big brain makes you human – count your neurons when you count your blessings
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Believe Should Unwind? Look at These Scaled down Games
- How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- Italy now recognizes the crime of femicide and punishes it with life in prison
- 5 VIPs That Changed Style
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
